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ABSTRACT
Hepatocellular carcinoma (HCC) is a major problem of global health.Transarterial 
chemoembolization (TACE) is the treatment of choice for unresectable HCC. The TACE 
is routinely conducted in major hospitals in Indonesia, however it rarely published.
The use of modified response in evaluation criteria in solid tumors (mRECIST) was 
introduced as an accurate method of measuring tumor response in HCC. This study 
aimedto investigate the factorsaffecting tumor response to TACE therapy in HCC 
patients by using mRECIST. It was a retrospective cohort study conducted on 30 patients 
who successfully underwent the first TACE procedure in the Department of Radiology, 
Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia from January 2016 
to August 2019. The multiphase abdominal computed tomography before and after 
as well as  laboratory examination results before TACE were collected and analyzed. 
Chi-Square and Spearman-tests were used for the statistical analysis. A significant 
relationship between tumor location (p=0.016), number of tumor (p=0.001) and Child-
Pugh score with tumor response to TACE therapy (p = 0.016) was observed. Solitary 
tumors tend to have a better therapeutic response, meanwhile, tumors located in the 
left lobe of patients with Child-Pugh B scores showed a decreased tumor response. 
Furthermore, no a significant relationship between age (p=0.920), sex (p=0.303), tumor 
size> 5 cm (p=0.082) and alpha-fetoprotein (AFP) levels (p=0.414) with tumor response 
was observed. In conclusion, TACE is preferably therapy for multinodular and 
unresectable HCC. Tumor response after TACE can be well assessed using mRECIST. 
The factorsaffecting tumor response to TACE therapy arenumber of tumor, location, 
and Child-Pugh score.
ABSTRAK
Hepatocellular carcinoma (HCC) adalah masalah utama kesehatan global. Transarterial 
chemoembolization (TACE) adalah pengobatan pilihan untuk HCC yang tidak dapat 
dioperasi. TACE dilakukan rutin di rumah sakit utama di Indonesia, namun demikian 
jarang dipublikasikan. Penggunaan modified response in evaluation criteria in solid 
tumors (mRECIST) diperkenalkan sebagai metode yang akurat untuk mengukur 
respons tumor pada HCC. Penelitian ini bertujuan untuk mengkaji faktor-faktor yang 
mempengaruhi respon tumor terhadap terapi (TACE) pada pasien HCC menggunakan 
mRECIST. Ini merupakan penelitian kohort retrospektif terhadap 30 pasien yang 
telah  menjalani TACE pertama di Bagain Radiologi RSUP Dr. Wahidin Sudirohusodo 
Makassar mulai bulan Januari 2016 sampai Agustus 2019. Hasil pemeriksaan 
computed tomography abdomen dengan kontras multifase sebelum dan sesudah serta 
hasil laboratorium sebelum TACE dikumpulkan dan dianalisis. Uji Chi-Square dan 
Spearman digunakan untuk analisis statistik. Terdapat hubungan bermakna antara 
lokasi tumor (p=0,016), jumlah tumor (p=0,001) dan skor Child-Pugh dengan respon 
tumor terhadap terapi TACE (p=0,016). Tumor soliter cenderung memiliki respon 
terapi lebih baik sementara tumor yang berlokasi di lobus kiri atau pasien dengan 
skor Child-Pugh B menunjukkan respon tumor yang menurun. Selanjutnya, tidak ada 
hubungan bermakna antara usia (p=0,920), jenis kelamin (p=0,303), ukuran tumor >5 
cm (p=0,082) dan kadar alpha-fetoprotein/AFP (p=0,414) dengan respon tumor terhadap 
TACE. Dapat disimpulkan bahwa TACE merupakan terapi pilihan untuk penyakit HCC 
yang multinodular dan tidak dapat dioperasi. Respon tumor setelah TACE dapat dinilai 
dengan baik menggunakan mRECIST. Faktor-faktor yang mempengaruhi respons 
tumor terhadap TACE adalah jumlah tumor, lokasi, dan skor Child-Pugh.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is 
a major global health problem. Itranks 
sixth as the most diagnosed cancer and 
fourth as a cause of death from cancer 
worldwide.1 The HCC is formed through 
the hepatocarcinogenesis process, 
in which the transformation of non-
malignant liver cells into hepatocellular 
carcinoma gradually.2 The molecular 
and cellular mechanisms underlying the 
change of cells that were not malignant 
to HCC are not yet fully understood3 and 
the risk factors that thought to trigger 
HCC vary from region to region.1
In contrast to other liver tumors, 
HCCs almost exclusively is supplied 
by hepatic arteries. Uniquely, the liver 
has double vascularization with 75 to 
80%  portal vein components and 20 to 
25% arterial components which allow 
eradication of the tumor through the 
feeding artery without disrupting the 
healthy part of the liver.4
Transarterial chemoembolization 
(TACE) is the treatment of choice for 
unresectable HCC.5 Currently, TACE is a 
standard of care for HCC patients who 
belong to the BCLC stage B group, which 
has large or multinodular tumors with 
relatively proper liver function (child-
pugh A or B ).There is no evidence of 
vascular invasion or extrahepatic spread 
and performance status that is still active 
(ECOG PS 0-1).6
The TACE procedure requires 
injected embolic agent directly into the 
tumor feeding artery to isolate the tumor 
from its primary source of nutrition. 
This action causes ischemic necrosis of 
the targeted tumor.7 After TACE, tumor 
response usually assessed to see the 
effectiveness of therapy. Previously the 
response in evaluation criteria in solid 
tumors (RECIST) method was used to 
evaluate tumor response. Recently, the 
use of modified response in evaluation 
criteria in solid tumors (mRECIST), a 
modification of the RECIST method, was 
introduced as a more accurate method of 
measuring tumor response in HCC.8
Previous studies have linked 
tumor responses to factors that are 
considered to play a role or are part of 
the development of HCC disease. Tumor 
location and tumor size have broadly 
recognized as a significant predictive 
factor of response for TACE.7,9Other 
studies have linked tumor responses with 
demographic factors, Child-Pugh scores, 
even with alpha-fetoprotein (AFP) levels, 
a serum marker of liver malignancy that 
judged to be sufficiently pathognomonic 
for an HCC.10-11
TACE practices is rarely published 
even though this procedure is routinely 
conducted in major hospitals. TACEis one 
of the therapies of choice in unresectable 
HCC in Indonesia. Therefore, before 
performing this procedure, the physician 
needs to predict whether the TACE would 
be useful, particularly while considering 
other therapeutic modalities. This study 
aimed to investigate the factors that 
can influence tumor response to TACE 
therapy in HCC patients.
MATERIALS AND METHODS
Patients
Thirty-two HCC patients who had 
successfully undergone the first TACE 
procedure at Dr. Wahidin Sudirohusodo 
General Hospital, Makassar from 
January 2016 to August 2019 were 
selected in this study. The inclusion 
criteria were all patients diagnosed with 
HCC from multiphase abdominal CT scan 
results, who were not candidates for 
resection. Two of them were excluded 
due tounderwent other therapies before. 
Of the 30 patients, tumor response 
wereassessed based on radiological and 
laboratory supportive results.
TACE procedure
TACE procedure was carried out 
through the femoral artery approach 
with fluoroscopic guidance and a co-
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axial catheter system to incorporate 
local doses of chemotherapy agents 
and concentrated directly into feeding 
vessels of the tumor. This procedure 
was followed by embolization using 
temporary particle material.
TACE was preceded by injection of 
doxorubicin and lipiodol, which have 
mixed into a homogeneous emulsion. 
The dose of doxorubicin adjusted 
according to the size of the tumor. The 
emulsion mixture wasthen injected 
until static in second or third orde of the 
right or left hepatic arteries. Emulsion 
injection was followed by a dose of a 
mix of embolic agents and water-soluble 
contrast media to maintain the drug in 
the tumor and to provide an embolic 
effect. The embolic agent used for this 
procedure wasgel foam particles. Gel 
foam was used to induce or increase 
ischemic tumor necrosis and prevent 
drug wash-out, thereby maintaining 
high local concentrations.
The procedure performed on large 
HCCs was partial TACE, aimed to prevent 
the full effects of necrosis, which 
can affect the liver function overall. 
Therefore, the TACE procedure at our 
institution was planned to carried out in 
stages with controlled drug dosages.
Evaluation of tumor response 
Tumor response assessment 
wasconducted using the mRECIST 
(FIGURE1). The assessment was carried 
out from the multiphase abdominal CT, 
which performed four weeks after initial 
treatment. According to mRECIST, the 
overall tumor response was determined 
based on the target and non-target lesion 
response, and also the presence of a new 
lesion.8
FIGURE 1. Assessment of target lesions on the axial cut of multiphase abdominal CT 
using RECIST vs.  mRECIST method. A. The total diameter of target lesions 
obtained from the sum of the longest tumor axis. B. The total diameter was 
obtained from the sum of the longest tumor axis outside the area of necrosis
BA
RECIST mRECIST
Target lesions response
Target lesions werethe primary 
lesion detected in the liver with typical 
enhancement in the arterial phase and 
wash-out in the venous phase. Target 
lesions must be measurable (> 1 cm) 
in at least one dimension. In multiple 
HCCs, the two largest of target lesions 
were chosen to represent the tumor 
size. The measurement results of target 
lesions were stated in four categories, 
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namely1) complete response (CR) if loss 
of intratumoral artery warming in all 
target lesions;2) partial response (PR) if 
there is a reduction in the total tumor 
diameter>30%; 3) progressive disease 
(PD) if an increase in overall tumor 
diameter> 20%; 4) stable disease (SD) 
ifall cases that cannot be grouped into 
PR or PD.
 
Non-target lesions response
All other lesions besides the target 
lesions were identified as a non-target 
lesion. Measurement of non-target 
lesions wasnot required, but their 
presence and absence werenoted 
during the follow-up. Disappearance 
of intratumoral enhancement of non-
target lesions was noted as a complete 
response. Persistence in intratumoral 
enhancement of non-target lesions 
indicated a stable disease (FIGURE 
2). The presence of one or more non-
target lesions identified as a progressive 
disease.
FIGURE 2. A. An axial cut of multiphase abdominal CT shows several small lesions in the 
liver with intratumoral enhancement in the arterial phase which identified as 
non-target lesions. The main tumor was on another cut of the image. B. One 
month after undergoing TACE therapy, in the same cut as the previous picture, 
lipiodol retention was seen in the branches of the right hepatic artery with a 
reduction in the number of lesions. Persistent intratumoral enhancement was 
seen in several non-target lesions. This finding identified as an incomplete re-
sponse or stable disease of non-target lesions.
A B
All lesions that werenot measurable 
on CT identified as non-target lesions.8 
Some of the findings that suggest a non-
target lesion including a) portal venous 
thrombosis; b) porta hepatic lymph 
node. Lymph nodes detected in the 
hepatic port can considered malignant if 
the shortest axis of the lymph node is> 20 
mm; c) pleural effusion and ascites.
New lesion
The presence of new focal lesions 
that enhancing in the arterial phase and 
wash-out in the venous phase must be 
identified as new HCC lesion.
The overall tumor response
The overall tumor response wasa 
combination of target lesions response, 
non-target lesions response, and the 
presence of new lesions (TABLE 1). If 
the target and non-target lesions were 
complete response (CR) without any new 
lesion found, then the overall response 
was complete. If one of them (target 
or non-target) was a partial or stable 
response without any new lesion, then 
the overall response was partial response 
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(PR). If both were stable without any 
new lesion, then the overall response 
was stable disease (SD). However, if one 
of them was progressive or there was 
a new lesion found, then the overall 
response was progressive disease (PD).
Statistical analysis
Informations were analyzed 
bivariate. Age, sex, location of primer 
TABLE 1. Tumor response assessment in mRECIST
Target lesions Non-target lesions New lesion Tumor response
Complete response Complete response (-) Complete response
Complete response Stable disease (-) Partial response
Partial response Complete/stable (-) Partial response
Stable disease Complete/stable (-) Stable disease
Progressive disease Any response (+) or (-) Progressive disease
Any response Progressive disease (+) Progressive disease
Any response Any response (+) Progressive disease
right lobe. 93.3% of patients had multiple 
tumors, and the tumor size varied 
between 6.6to 19.4 cm with a mean of 
12.16 ± 3.17 cm. 83.3% of patients had 
a Child-Pugh class A score, and 63.3% 
had AFP levels>400 IU/mL. The baselines 
characteristicof patients are presented 
in TABLE 2.
TABLE 2. Baselines characteristic
Characteristics n(%) Mean± SD
Age (years old) 55.06±10.33
Sex
•	 Male 27(90)
•	 Female 3 (10)
Main tumor location
•	 Right lobe 25(83.3)
•	 Left lobe 5 (16.7)
Number of tumor
•	 Single 2(6.7)
•	 Multiple 28 (93.3)
Maximum tumor size (cm) 12.16±3.17
Child-Pughscore
•	 Class A 25(83.3)
•	 Class B 5 (16.7)
AFP levels
•	 <400 IU/mL 11(36.7)
•	 >400 IU/mL 19 (63.3)
tumors, number of tumors, largest 
tumor size, child-pugh score, and AFP 
levels were associated with tumor 
response after TACE. The Chi-Square 
and Spearman statistical tests were 
performed to evaluate the correlation 
between variables. The significance 
of statistical analysis was considered 
significant if the p value <0.05.
RESULTS
Demographic and tumor   characteristics 
The result showed of the 30 patients 
involved in this studyaged varyfrom 
41to 74 years with a mean of 55.06 ± 
10.33 years. 90% of patients were male, 
and 83.3% had a primary tumor in the 
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Factors associated with tumor 
response
Among the 30 patients, none achieve 
the CR, 10 % were PR, 73.3 % were 
SD, and 16.7 % were PD according to 
mRECIST criteria. A significant higher 
PR rate was observed in solitary tumors 
than those with multiple tumors (100% 
vs. 3.6 %; p=0.001).  A significant higher 
PD rate was observed in left lobe tumors 
than thosein right lobe tumors (60% vs. 
8%; p=0.016), and in Child-Pugh score B 
compared to child-pugh score A (60% vs. 
8%; p=0.016). There was no difference 
according to age (p=0.92) or by sex 
(p=0.303), tumor size (p=0.082), or AFP 
serum level (p=0.4). The main results are 
summarized in TABLE 3.
TABLE 3. Tumor response of 30 patients according to mRECIST
Variables
Tumor Response n(%)
pPartial 
response
Stable 
disease
Progresive 
disease
Sex
•	 Male 2 (7.4) 20 (74.1) 5 (18.5)
0.303
•	 Female 1 (33.3) 2 (66.7) 0
Age 0.920
Main tumor location
•	 Right lobe 3 (12) 20 (80) 2 (8)
0.016
•	 Left lobe 0 2 (40) 3 (60)
Number of tumor
•	 Solitary 2 (100) 0 0
0.001
•	 Multiple 1 (3.6) 22 (78.6) 5 (17.8)
Maximum tumor size 0.082
Child-Pugh score
•	 Class A 3 (12) 20 (80) 2 (8)
0.016
•	 Class B 0 2 (40) 3 (60)
AFP levels
•	 < 400 IU/mL 2 (18.2) 8 (72.7) 1 (9.1)
0.414
•	 > 400 IU/mL 1 (5.2) 14 (73.7) 4 (21.1)
DISCUSSION
Most HCC patients in this study 
sample were men with the age group 40-
49 years. The American Cancer Society 
reported that the incidence of hepatoma 
in men is three times higher than in 
women in most regions of the world with 
the highest frequency at the age of 45-65 
years.1 Age and sex were not significantly 
correlated with tumor response to TACE. 
Men and women, both showed the same 
patterns of tumor response. There was 
no tendency for an increase in tumor 
response to age. Nishikawa et al.11 also 
reported that the therapeutic response 
in hepatoma patients undergoing TACE is 
not affected by age or sex. Bryant et al.12 
also reported that there is no significant 
differences in age or gender between 
the favorable response and inadequate 
response of patients to TACE.
Tumor location was strong 
correlated with tumor response to TACE 
therapy in this study. Tumors located in 
the right lobe of the liver generally had 
a stable tumor response.In contrast, 
tumor located in the left lobe of the liver, 
had a tumor response that tends to be 
progressive. Previous studies reported 
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that tumor location is an important 
predictive factor for disease progression 
and tumor response to therapy. Miki 
et al.7 reported that the efficacy of 
TACE increases in HCCs located in the 
peripheral zone of the right lobe and 
medial segment. Furthermore, the HCC 
located in first and fourth liver segment 
may weakens the complete response.9 To 
explain why this location is a pejorative 
factor, the substantial variations of the 
liver vascularization (especially for 
the caudate segment) and the common 
intrahepatic collaterals and anastomosis 
in the center of the liver, running 
between right and left hepatic arteries 
should kept in mind.13
The number of tumors were 
correlated with tumor response to TACE 
therapy in this study. All patients with 
a single tumor showed a partial tumor 
response, whereas patients with multiple 
tumors showed a varied but generally 
stable tumor response. This result is 
proper, considering more tumors as 
much vascularity. In a single HCC, the 
interventionist can close the main 
arterial flow that supplies the tumor. 
Conversely in multinodular HCC, the 
interventionist generally has to choose 
which arterial flow will be shut and is 
usually selected in the most significant 
tumor especially if the nodules spread in 
both lobes.
In this study, the HCC patients 
generally had tumor sizes that tended to 
be large, with the smallest size of 6.6 cm 
and the largest of 19.4 cm. However, the 
tumor size did not correlate with tumor 
response to TACE therapy in this study. 
Previous studies reported that tumor size 
is a significant predictive factor in tumor 
response to TACE. Vessele et al.9 reported 
that tumor size <5cm is a predictive 
factor for CR. Moreover, Bryant et al.12 
demonstrated the better response rate 
in the <3 cm tumor group than in the 
3 to 5 cm or>5cm tumors after TACE.12 
This might explain there were none of 
the samples reached CR and tumor size 
did not show a correlation with tumor 
response in this study. When the tumor 
size is>5cm, then CR is challenging to 
achieve, as well as the tumor response 
to therapy becomes difficult to predict. 
Some experts agree that a large size of 
HCC (> 10 cm) have a worse therapeutic 
intervention with the possibility of 
more significant vascular invasion and 
extrahepatic spread.14
Child-Pugh scores were correlated 
with tumor response to TACE therapy in 
this study. HCC patients with a Child-Pugh 
A score showed a better tumor response 
compared to patients with a Child-Pugh 
B score. It seems that the efficacy of 
TACE tends to decrease with decreasing 
liver function. Miki et al.7 also reported 
that the efficiency of TACE increases in 
patients with Child-Pugh A score.
In 2001, European Association for the 
Study of the Liver-European Organization 
for Research and Treatment of Cancer 
(EASL-EORTC) concluded that serum 
AFP levels are one of the criteria used as 
a reference in determining the diagnosis 
of HCC. In 2005, in collaboration with the 
American Association for the Study of 
Liver Diseases (AASLD), the non-invasive 
criteria were revised, and the evaluation 
of AFP serum levels removed from the 
diagnostic algorithm.6 However, some 
experts still consider that AFP levels> 
400 IU/mL are reliable marker of HCC, 
and as important predictive factor for 
prognostic therapy. In this study, AFP 
levels were not correlated with tumor 
response to TACE. Patients with AFP 
levels below or above 400 IU/mL did not 
show significant differences in tumor 
response. Previous study reported that 
the sensitivity of AFP in diagnosing 
hepatoma is only 54% and the prognostic 
value is low.15
Some limitations of this study were 
reported including starting from a 
small sample size and then response 
was observed after the first cure, 
while several tumors need more than 
one cure to reach complete response, 
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unusually large tumors. Finally, the 
lack of histological proof can lead to 
overestimated responses.
CONCLUSION
Tumor response to TACE varies 
among the HCC patients. It increases in 
HCC patients with solitary tumors, while 
the response decreases in tumors located 
in the left lobe and patients with Child-
Pugh B scores. Clinicians should consider 
these results before determining the 
most definitive therapy for HCC patients.
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